Treating patients with iMCD

Importance to Treat

Even after it’s diagnosed, iMCD often leads to hospitalization

60% of patients were hospitalized the first year after iMCD diagnosis

Idiopathic multicentric Castleman disease (iMCD) is a progressive disease with a poor prognosis^2,3
Regardless of severity of clinical presentation, high rates of hospitalizations and ED visits are observed in patients with iMCD²

^aRetrospective database claims analysis that assessed hospitalizations, ED visits, iMCD-related comorbidities, and organ failure in US patients with Castleman disease (over 30 million) between January 1, 2017, and December 31, 2019. Minor criteria from the Castleman Disease Collaborative Network (CDCN) diagnostic criteria were applied to ensure that the patients had iMCD.^1,3

Despite diagnosis, most patients with iMCD are undertreated⁴

More than 70% of patients receive steroid monotherapy

Treating patients with iMCD

There are various therapies being used in the treatment of patients with iMCD. The CDCN, the same group that published the first consensus diagnostic criteria, has developed formal guidelines for the treatment of iMCD.⁵

Timely
Diagnosis

Timely diagnosis and appropriate treatment can help bring the symptoms of iMCD under control.³

Ongoing
Treatment

Considering the chronic and progressive nature of iMCD, patients will need to receive ongoing treatment to keep their symptoms under control.^5,6

Following Treatment Guidelines

Evidence-based treatment guidelines have been developed to help healthcare professionals treat their patients with iMCD.⁵

Different journeys. Same fighting spirit.

Hear from the people who have been fighting iMCD for years, and learn how they have dealt with some of the challenges they have experienced.

Jessica

In 2005, Jessica began experiencing fever, night sweats, and swollen lymph nodes. After 14 long years, she found out that she has iMCD. Watch her story to learn about her journey to diagnosis.

Carl

In 1985, there weren’t any guidelines to diagnose iMCD. But that didn’t stop Carl from getting an accurate diagnosis for his rare disease. Watch his journey to learn about the path he took to finally get diagnosed with iMCD.

Frank & Dina

iMCD has troubled Frank for years. But with his wife Dina by his side, he was never going to back down. Watch the video to learn about the ups and downs they faced during their journey to diagnosis.

Sign up for more on iMCD

*First name

*Last name

*Email

*ZIP code

*Phone number

NPI number

I would like to register for Know iMCD , and I acknowledge the .

Please enter a valid First Name. Please enter a valid Last Name. Please enter a valid Email Address. Please enter a valid ZIP code. Please enter a valid Phone Number. Please choose a Provider Type. Please choose a Medical Specialty.

*Required.

References:

Mukherjee S, Martin R, Sande B, et al. A longitudinal population level analysis of healthcare resource utilization, comorbidity, and survival in idiopathic multicentric Castleman disease patients. Presented at: 62nd American Society of Hematology (ASH) Annual Meeting and Exposition; December 5-8, 2020; virtual meeting.
Mukherjee S, Martin R, Sande B, et al. A longitudinal population level analysis of healthcare resource utilization, comorbidity, and survival in idiopathic multicentric Castleman disease patients. Blood. 2020;136(suppl 1):11.
Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-1657.
Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022;6(2):359-367.
van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115 -2124.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for B-Cell Lymphomas V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 29, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.